CHOC Children's Researcher Detail

CHOC Docs

Share |

Raymond Y Wang, MD

Dr. Wang has staff privileges at CHOC in Orange

Location:
Orange, CA

Specialty:
Metabolic Disorders

Research Focus:
Lysosomal storage disorders

Published Works:

Jump to list

Office and Contact Information

CHOC Children's Specialists
1201 W La Veta
Orange, CA 92868
phone: (714) 509-8852
fax: (714) 509-8362
map & directions

Web Site:
http://www.choc.org/specialists

Physician / Researcher Bio

Raymond Wang, M.D. is the director of multidisciplinary lysosomal storage disorder program at CHOC Children’s and a board certified pediatrician and biochemical genetics specialist. He attended Stanford University where he was a member of Phi Beta Kappa and graduated with a bachelor’s degree in biological sciences. He earned his medical degree from the University of California, Los Angeles (UCLA) where he was a member of Alpha Omega Alpha. He did his internship and residency in medical genetics and pediatrics at Cedars-Sinai Medical Center where he also attended the center’s medical genetics training program. He completed his fellowship in biochemical genetics at the UCLA Intercampus. In 2006, Dr. Wang received the American College of Medical Genetics’ Genzyme Fellowship in Biochemical Genetics Award. In the same year, he also received the Cedars-Sinai Medical Center’s Paul Rubenstein Prize for Excellence in Resident Research.

Research

Dr. Wang’s research concentrates upon a category of inherited conditions called lysosomal storage disorders, which result in severe, progressive multisystemic symptoms from ongoing accumulation of undegraded substrates within the lysosomal compartment of the cell. Previously untreatable and leading to early death, treatments to reduce the substrate storage such as hematopoietic stem cell transplantation and / or intravenous enzyme replacement therapy have beneficially changed the natural history of some lysosomal storage disorders.

As long-term survivors with storage disorders are becoming adolescents and young adults, progressive symptoms in other tissues resistant to these treatments have been recognized. Dr. Wang’s research focuses upon the development of treatment for these refractory organ systems, and upon the refinement of novel, non-invasive biomarkers to follow treatment progress and predict future outcomes. He is currently studying the safety and efficacy of intra-articular alpha-iduronidase injections in a canine model of mucopolysaccharidosis type I, and assessing the utility of carotid intima-media thickness as a predictor of cardiovascular dysfunction and disease in patients with mucopolysaccharidoses.

Board Certifications

Genetics
Clinical and Biochemical Genetics

Published Works

Wang RY, Bodamer OA, Watson MS, Wilcox WR; on behalf of the ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals. Epub ahead of print, Genet Med. 2011 Apr 15.

Reinstein E, Wang RY, Zhan L, Rimoin DL, Wilcox WR. Ehlers–Danlos type VIII, periodontitis-type: Further delineation of the syndrome in a four-generation pedigree. Am J Med Genet Part A 2011; 155: 742–747.

Sass JO, Fischer K, Wang RY, Christensen E, Scholl-Bürgi S, Chang R, Kapelari K, Walter M. D-glyceric aciduria is caused by genetic deficiency of D-glycerate kinase (GLYCTK). Hum Mutat. 2010; 31: 1280-1285.

Puckett R, Lorey F, Rinaldo P, Lipson M, Matern D, Sowa M, Levine F, Chang R, Wang RY, Abdenur JE. Maple syrup urine disease: further evidence that variant forms cannot be detected by newborn screening. Mol Genet Metab. 2010; 100: 136-142.

Wang RY, Cambray-Forker EJ, Ohanian K, Karlin DS, Covault KK, Schwartz PH, Abdenur JE. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol Genet Metab. 2009; 98: 406-411.

Wang RY, Abe JT, Cohen AH, Wilcox WR. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage. Journal of Inherited Metabolic Disease, Epub, 10/21/2008

Wang RY, Lelis A, Mirocha J, Wilcox WR. Fabry disease female heterozygotes are not just “carriers,” but have a significant burden of disease and impaired quality of life. Genet Med, 2007; 9: 34-45.

Wang RY, Kangarloo H, Jordan SH. Cystic Renal Disease. Emery & Rimoin’s Principles and Practice of Medical Genetics, 5th ed. Rimoin DL, Connor JM, Pyetriz RE, Korf BR, eds. 2007.

Wang RY, Jones JR, Chen S, Rogers RC, Friez MJ, Schwartz CE, Graham JM Jr. A Previously Unreported Mutation in a Currarino Syndrome Kindred. Am J Medical Genet Part A 2006; 140: 1923-1930.

Wang RY, Visootsak J, Danielpour M, Graham JM Jr. Midline defects in FG syndrome: does tethered spinal cord contribute to the phenotype? J Pediatr 2005; 146: 537-541.

Wang RY, Martinez-Frias ML, Graham JM Jr. Infants of Diabetic Mothers are at Increased Risk for the Oculo-auriculo-vertebral Sequence: A Case-Based and Case-Control Approach. J Pediatr 2002; 141: 611-617.

Wang RY, Earl D, Ruder RO, Graham JM Jr. Syndromic Ear Anomalies and Renal Ultrasounds. Pediatrics 2001; 108: E32.

Presentations
Wang R, Cambray EJ, Ohanian K, Karlin D, Abdenur JA. Early initiation of treatment for MPS reduces severity of brain imaging abnormalities. 2009 WORLD (“We’re Organizing Research on Lysosomal Diseases”) Meeting, San Diego, CA: 2/16/09 – 2/19/09.

Wang R, Abe JT, Cohen AH, Wilcox WR. Enzyme Replacement Therapy Stabilizes Pulmonary Fabry Disease Associated with Respiratory Globotriaosylceramide Storage. 2008 Society of Inherited Metabolic Disorders Meeting, Asilomar, CA: 3/2/08 – 3/5/08.

Wang R, Lelis A, Mirocha J, Wilcox WR. Fabry disease female heterozygotes are not just “carriers,” but have a significant burden of disease and impaired quality of life. 2007 American College of Medical Genetics Meeting, Nashville, TN: 3/21/07 – 3/25/07.

Wang R, Lelis A, Mirocha J, Wilcox WR. Fabry disease female heterozygotes are not just “carriers,” but have a significant burden of disease and impaired quality of life. 2006 Lysosomal Disease Network Symposium, Orlando, FL: 12/7/06 – 12/9/06.

Wang R, Lelis A, Mirocha J, Wilcox WR. Fabry disease female heterozygotes are not just “carriers,” but have a significant burden of disease and impaired quality of life. 2006 International Congress for Inborn Errors of Metabolism, Chiba, Japan: 9/12/06 – 9/15/06.

Wang R, Lelis A, Mirocha J, Wilcox WR. Fabry disease female heterozygotes are not just “carriers,” but have a significant burden of disease and impaired quality of life. 2006 Cedars Sinai Medical Center Rubinstein Award Ceremony, Los Angeles, CA: 5/23/2006.

Wang R, Jones JR, Chen S, Rogers RC, Friez MJ, Schwartz CE, Graham JM Jr. A Previously U

FIND A CHOC DOC

RELATED SERVICES:

METABOLIC LAB

RELATED SPECIALTIES:

METABOLIC DISORDERS